Kina Tirzepatide Review: Injection, Drops & Billing Terms

Kina lists two compounded tirzepatide options for women in menopause and midlife: $249 per month for injections and $229 per month for sublingual drops. Its broader $169 first-month and $199 ongoing GLP-1 advertising should not be treated as the named tirzepatide price. The treatment page describes a clinician deciding whether a prescription is appropriate; purchasing a particular preparation is not guaranteed.³

Kina connects patients with Arora Health & Aesthetics, LLC for clinical services. The Coivas and EOS Health reviews also discuss that group. A shared care organization does not establish the same prescription, pharmacy, price or contract across programs.^3,5

Compare the named price with the billing agreement

The weight-care page says the $25 consultation fee is covered, shipping is free, and the price stays the same at every dose. It advertises ongoing messaging, dose adjustments and side-effect support as included. These are current program claims, rather than an independently verified bill or a promise that a clinician will increase the dose. FSA/HSA eligibility is advertised; confirm reimbursement with your account administrator.³

The May 28, 2026 Terms tell a different billing story. Section 7 describes recurring membership plans for clinician access, messaging and care adjustments, with medication and supplements billed separately. That conflicts with the weight page and FAQ saying there are no membership fees. The Terms also describe the platform in connection with NAD+ wellness, so ask which agreement and charges govern the specific tirzepatide plan rather than assuming the general contract has been waived.^3,4,6

Before authorizing payment, obtain the total first charge, recurring charge, exact preparation and supplied quantity, and confirmation of whether a care fee is separate. The named monthly prices do not establish a particular dose or the number of vials or drop bottles supplied. The $30 introductory discount is presented within general GLP-1 advertising; the public wording does not establish a $219 injection or $199 drop offer.³

Cancellation and refunds depend on the stage

The FAQ says there are no long-term contracts and that patients can pause or cancel in their account. Section 7 similarly allows account cancellation. Neither statement means an existing payment or dispatched prescription will be refunded, and the reviewed contract does not give a precise number of hours before a renewal or processing cutoff.^4,6

Under section 8, someone canceling before clinician review may request a full refund. Membership fees become nonrefundable once a clinician reviews the intake, and shipped medication orders are nonrefundable. Requests go to care@trykina.com. This is not a blanket money-back promise for clinical denial or dissatisfaction: review can occur even when no medication is prescribed. Confirm the order stage and any next charge when asking to cancel.⁴

Who handles care and dispensing?

The care disclosures identify Arora Health & Aesthetics at 300 Lenora Street, Seattle, with medicalcompliance@arorahealthgroup.com as its contact. The medical-team page names Sean and Shannon Arora and describes ongoing oversight. However, Shannon's listing uses both a PharmD/clinical-lead description and a physician/chief-medical-officer biography. Those inconsistent labels do not independently establish an individual's qualifications or who will treat you. Confirm your treating clinician and their state authorization.^3,5

Section 6 names F&F Pharmacies Inc dba Jungle Jim's Pharmacy, at 5484 Dixie Highway, Fairfield, Ohio, as a partner. The FAQ refers more generally to U.S. partner pharmacies and says formulations or fulfillment may vary with state restrictions. The named partner is useful disclosure, but it does not identify the facility assigned to every tirzepatide prescription. Confirm the actual dispensing pharmacy and preparation before fulfillment.^4,6

Kina limits availability to jurisdictions where the affiliated medical provider and pharmacy are authorized. Its displayed LegitScript link is not an independent certification determination: the public checker did not yield a completed status result. No current certification or individual professional license is independently verified here.^3,5,7

Injection and drops have different evidence

Both preparations are described as compounded. Compounded tirzepatide is not itself an FDA-approved finished product. The pivotal injection trials do not establish equivalent absorption, dosing or outcomes for sublingual drops; discuss that distinction with the clinician. Our compounding legal-status guide explains the broader regulatory setting.³

Labeled tirzepatide risks include pancreatitis, gallbladder problems and the thyroid C-cell tumor warning. Read about Zepbound side effects, gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

Before choosing a program

Kina's useful distinction is menopause-focused care with two named monthly tirzepatide options. Resolve the membership contradiction and refund stage before paying, and confirm the selected route and dispenser. The CoreAge Rx and Coivas reviews provide other program-specific disclosures; their prices and policies do not transfer to Kina. The provider comparison offers a broader starting point.